Literature DB >> 15895193

Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Stanley P L Leong1, Mohammed Kashani-Sabet, Renee A Desmond, Robert P Kim, Dennis H Nguyen, Kensho Iwanaga, Patrick A Treseler, Robert E Allen, Eugene T Morita, Yuting Zhang, Richard W Sagebiel, Seng-Jaw Soong.   

Abstract

Selective sentinel lymphadenectomy (SSL) following preoperative lymphoscintigraphy is the most significant recent advance in the management of patients with primary melanoma. This study evaluates the prognostic value of sentinel lymph node (SLN) status and other risk factors in predicting survival and recurrence in patients with primary cutaneous melanoma. From October 1993 to July 1998 a series of 412 patients with primary invasive melanoma underwent SSL at the UCSF/ Mt. Zion Melanoma Center. The outcome of 363 evaluable patients is summarized in this study. The factors related to survival and disease recurrence were analyzed by Cox proportional hazard regression models. The overall incidence of patients with positive SLNs was 18%. Over a median follow-up of 4.8 years, the overall mortality rate in patients with primary cutaneous melanoma was 18.7%, and 74 recurrences occurred (20.4%). Mortality was significantly related to SLN status [HR = 2.06; 95% Confidence interval (CI) 1.18, 3.58], angiolymphatic invasion (HR = 2.21; 95% CI 1.08, 4.55), ulceration (HR = 1.79; 95% CI 1.02, 3.15), mitotic index (HR =1.38; 95% CI 1.01, 1.90), and tumor thickness (HR = 2.20, 95% CI 1.21, 3.99). Factors significantly related to disease-free survival included SLN status (HR = 2.09; 95% CI 1.31, 3.34), tumor thickness (HR = 1.89; 95%. CI 1.20,2.98), and age (HR= 1.26 95% CI 1.08, 1.47). SLN status was the most significant factor for melanoma recurrence and death. Other important predictors include tumor thickness, ulceration, lymphatic invasion, and mitotic index.

Entities:  

Mesh:

Year:  2005        PMID: 15895193     DOI: 10.1007/s00268-005-7736-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  44 in total

1.  The natural break points for primary-tumor thickness in clinical Stage I melanoma.

Authors:  C L Day; R A Lew; M C Mihm; M N Harris; A W Kopf; A J Sober; T B Fitzpatrick
Journal:  N Engl J Med       Date:  1981-11-05       Impact factor: 91.245

2.  Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy.

Authors:  J F Thompson; R F Uren; H M Shaw; W H McCarthy; M J Quinn; C J O'Brien; R B Howman-Giles
Journal:  J Am Coll Surg       Date:  1999-08       Impact factor: 6.113

3.  Outcome of patients with melanoma and histologically negative sentinel lymph nodes.

Authors:  M A Gadd; A B Cosimi; J Yu; L M Duncan; L Yu; T J Flotte; W W Souba; M J Ott; L S Wong; A J Sober; M C Mihm; F G Haluska; K K Tanabe
Journal:  Arch Surg       Date:  1999-04

Review 4.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Authors:  Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

6.  Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma.

Authors:  David A Biddle; Harry L Evans; Bonnie L Kemp; Adel K El-Naggar; Jeff D Harvell; Wain L White; Sammy S Iskandar; Victor G Prieto
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

7.  Tumor thickness and prognosis in clinical stage I malignant melanoma.

Authors:  C P Karakousis; L J Emrich; U Rao
Journal:  Cancer       Date:  1989-10-01       Impact factor: 6.860

8.  The orderly progression of melanoma nodal metastases.

Authors:  D Reintgen; C W Cruse; K Wells; C Berman; N Fenske; F Glass; K Schroer; R Heller; M Ross; G Lyman
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

9.  Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.

Authors:  X Wang; R Heller; N VanVoorhis; C W Cruse; F Glass; N Fenske; C Berman; J Leo-Messina; D Rappaport; K Wells
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

10.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma.

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

View more
  7 in total

1.  Sentinel lymph node biopsy in melanoma.

Authors:  Matthew T Hueman; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2008-11-08

2.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Authors:  Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

4.  Utility of sentinel lymph node biopsy for solitary dermal melanomas.

Authors:  Yinin Hu; Puja Shah; George J Stukenborg; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2015-02-24       Impact factor: 3.454

5.  Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye.

Authors:  Yinin Hu; Patrick D Melmer; Craig L Slingluff
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

6.  Melanoma controversies: clinical significance of nodal micrometastases and the future of melanoma vaccines.

Authors:  Kelly M McMasters
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

7.  Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety.

Authors:  John E Hanks; Kevin J Kovatch; S Ahmed Ali; Emily Roberts; Alison B Durham; Joshua D Smith; Carol R Bradford; Kelly M Malloy; Philip S Boonstra; Christopher D Lao; Scott A McLean
Journal:  Otolaryngol Head Neck Surg       Date:  2020-02-11       Impact factor: 3.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.